Literature DB >> 28059910

Validation of MRI and Surgical Decision Making to Predict a Complete Resection in Pelvic Exenteration for Recurrent Rectal Cancer.

Wendy E Brown1, Cherry E Koh, Tim Badgery-Parker, Michael J Solomon.   

Abstract

BACKGROUND: The main predictor of long-term survival in patients with recurrent rectal cancer is surgical resection with a clear resection margin. MRI plays a role in patient selection and surgical planning.
OBJECTIVE: This study aimed to validate MRI in determining pelvic involvement by comparing MRI to histological outcomes, to assess the effect of MRI on surgical planning by comparing MRI findings with the surgical procedure, and to compare MRI anatomical involvement with resection outcome to assess if MRI can predict a clear resection margin.
DESIGN: Retrospective study reviewing prepelvic exenteration MRI and correlating organ, involving an MRI with pathological involvement and surgical outcomes. SETTINGS: Single quaternary referral center with a special interest in pelvic exenteration. PATIENTS: The patients included 40 men and 22 women with median age of 60 years who had locally recurrent rectal cancer. MAIN OUTCOME MEASURES: The accuracy of MRI as measured using sensitivity and specificity by correlating MRI involvement with pathological involvement was the primary outcome measured.
RESULTS: Recurrence in the anterior and central compartments was identified with accuracy on MRI and was likely to be associated with clear resection margins. MRI was less accurate at determining pelvic sidewall involvement. Lateral recurrence, high sacral, and nerve involvement were more likely to be associated with a positive resection margin. Sensitivity and specificity for pelvic sidewall structures was 46% and 91%. Involvement of nerve roots (60%-69%) and the upper sacrum (80%) on MRI was more likely to predict a positive resection margin than involvement of major pelvic viscera (22%). LIMITATIONS: This study was limited by its retrospective nature.
CONCLUSIONS: MRI findings can be used to help predict resection margin. Prospective work with MRI interpretation and close correlation and involvement by pathologists is needed to address imaging and surgical limitations at the pelvic sidewall and high posterior margin.

Entities:  

Mesh:

Year:  2017        PMID: 28059910     DOI: 10.1097/DCR.0000000000000766

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  6 in total

Review 1.  MRI of Tumors and Tumor Mimics in the Female Pelvis: Anatomic Pelvic Space-based Approach.

Authors:  Stephanie Nougaret; Ines Nikolovski; Viktoriya Paroder; Hebert A Vargas; Evis Sala; Sebastien Carrere; Raphael Tetreau; Christine Hoeffel; Rosemarie Forstner; Yulia Lakhman
Journal:  Radiographics       Date:  2019 Jul-Aug       Impact factor: 5.333

2.  Development of an Online Curriculum for Surgeons on the Use of Pelvic Magnetic Resonance Imaging in Rectal Cancer and Results of a Pilot Study.

Authors:  Sara Nofal; Yi-Qian Nancy You; George J Chang; Elizabeth G Grubbs; Brian Bednarski
Journal:  J Surg Res       Date:  2021-10-27       Impact factor: 2.192

Review 3.  Locally Recurrent Rectal Cancer According to a Standardized MRI Classification System: A Systematic Review of the Literature.

Authors:  Zena Rokan; Constantinos Simillis; Christos Kontovounisios; Brendan Moran; Paris Tekkis; Gina Brown
Journal:  J Clin Med       Date:  2022-06-18       Impact factor: 4.964

4.  Systematic review of classification systems for locally recurrent rectal cancer.

Authors:  Z Rokan; C Simillis; C Kontovounisios; B J Moran; P Tekkis; G Brown
Journal:  BJS Open       Date:  2021-05-07

Review 5.  The role of imaging in pelvic exenteration for gynecological cancers.

Authors:  Pamela Ines Causa Andrieu; Sungmin Woo; Eric Rios-Doria; Yukio Sonoda; Soleen Ghafoor
Journal:  Br J Radiol       Date:  2021-05-07       Impact factor: 3.629

Review 6.  Surgical treatment of locally recurrent rectal cancer: a narrative review.

Authors:  Zhaoya Gao; Jin Gu
Journal:  Ann Transl Med       Date:  2021-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.